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The work of Peutz in 1921 [1] and Jeghers et al. in 1949 [2]
led to the deﬁnition of the Peutz-Jeghers syndrome (PJS) at
a clinical level. The main characteristics are autosomal
dominant inheritance, lip pigmentations, gastro-intestinal
polyposis and various types of cancer. The identiﬁcation of
the LKB1/STK11 gene in 1998 [3, 4] allowed DNA-based
diagnosis of PJS and was the starting point for research into
the role of LKB1 in molecular pathways.
In the ﬁrst article of this special issue of Familial Can-
cer, Sebbagh et al. [5] discuss the role of LKB1 in AMPK-
dependent and AMPK-independent pathways. The review
by Udd & Ma ¨kela ¨ [6] focuses on the involvement of LKB1
in epithelial, mesenchymal, haematopoetic and germinal
cell differentiation. Jansen et al. [7] argue that Peutz-Je-
ghers polyp formation and malignant transformation are
separate manifestations of one molecular mechanism. The
role of LKB1 in lung cancer and possible therapeutic
implications are described by Sanchez Cespedes [8].
Two important clinical issues in PJS are complications
due to small bowel polyps and a high risk of malignancies,
both inside and outside the gastro-intestinal tract. Main
aspects of surveillance and treatment of PJS are summa-
rized by Latchford & Phillips [9] and Riegert-Johnson et al.
[10], respectively.
Insight into the molecular pathogenesis of PJS has led to
trials on chemoprevention and targeted therapy for this
patient group. Kuwada and Burt [11] consider the rationale
for mTOR inhibition as a chemopreventive strategy in PJS.
Subsequently, Sugars [12] shares her knowledge gained
from the PJS Online Support Group and through the
author’s personal experience as PJS patient. Finally, Lodish
and Stratakis [13] discuss the dermatological features of
PJS and the clinical differentiation of PJS from other
familial lentiginosis syndromes.
In France, seven regional groups called Canceropo ˆles
have coordinated the research units of scientiﬁc institutions
(Institute National de la Sante ´ et de la Recherche Me ´dicale,
Centre National de la Recherche Scientiﬁque), university
hospitals, comprehensive cancer centres, pharmaceutical
companies and biotechnology institutions. In Marseille, on
June 25th and 26th, 2010, the Canceropo ˆles ‘‘Provence
Alpes Co ˆte d’Azur’’ and ‘‘Lyon, Auvergne et Rho ˆne
Alpes’’ organised a cancer cell signalling meeting on ‘‘the
LKB1-AMPK pathway, from basic science to clinical
applications’’ (http://www.lkb1.com).
This meeting formed the inspiration for the series of
reviews published in this issue of Familial Cancer, written
by experts in the ﬁeld. The translation of basic research
into clinical practice is difﬁcult and challenging. We hope
that the current format of bringing aspects of research and
the clinic together will be helpful for both researchers and
those involved in the surveillance and treatment of PJS
patients.
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